Among patients in early TNM stage, 18 patients (24.32%) were FGL1 positive, 56 (75.68%) were FGL1 negative; In patients with advanced-stage tumor, 22 (62.86%) were FGL1 positive patients (62.86%), and 13 were FGL1 negative (37.14%). This evidence concerns the gene FGL1 and neoplasm.